Q3 EPS Estimate for Connect Biopharma Reduced by Analyst

Key Points

• HC Wainwright lowered Connect Biopharma’s Q3 2026 EPS estimate to a loss of $0.32 per share from its previous forecast of $0.30, while maintaining a “Buy” rating.
• Connect Biopharma’s latest quarterly results exceeded expectations, with a $0.27-per-share loss versus the $0.31 consensus estimate and revenue of $2.75 million versus $0.74 million expected.
• The stock opened at $0.90, near its 52-week low, while analysts maintain a “Moderate Buy” consensus rating and an average price target of $6.14; institutional investors own 58.72% of shares.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Friday, October 2nd. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.30). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Connect Biopharma's Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. The company had revenue of $2.75 million during the quarter, compared to analysts' expectations of $0.74 million.

CNTB has been the subject of several other research reports. BTIG Research decreased their price target on shares of Connect Biopharma to $5.00 and set a "buy" rating on the stock in a research note on Wednesday, September 30th. Wall Street Zen upgraded Connect Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings raised Connect Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 24th. Piper Sandler assumed coverage on Connect Biopharma in a research report on Friday, June 26th. They issued an "overweight" rating and a $7.00 target price on the stock. Finally, Canaccord Genuity Group lowered their price target on Connect Biopharma from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, September 16th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $6.14.

Connect Biopharma Stock Down 3.1%

Shares of NASDAQ CNTB opened at $0.90 on Tuesday. The firm has a market cap of $56.54 million, a price-to-earnings ratio of -0.75 and a beta of -0.16. The company's 50-day simple moving average is $1.87 and its 200-day simple moving average is $2.26. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 52-week low of $0.89 and a 52-week high of $3.82.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE acquired a new position in shares of Connect Biopharma during the 1st quarter valued at about $41,000. ADAR1 Capital Management LLC acquired a new stake in Connect Biopharma during the first quarter worth about $1,945,000. Knott David M Jr raised its stake in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company's stock worth $1,016,000 after purchasing an additional 187,835 shares during the period. Simplify Asset Management Inc. purchased a new position in Connect Biopharma during the first quarter worth about $135,000. Finally, Richmond Brothers Inc. acquired a new position in Connect Biopharma in the 4th quarter valued at about $489,000. Hedge funds and other institutional investors own 58.72% of the company's stock.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.